Skip to main
SGMT

SGMT Stock Forecast & Price Target

SGMT Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Sagimet Biosciences is expected to experience positive revenue growth in the coming years, driven by the potential success of denifanstat and TVB-3567 as effective and safe acne treatments. The company's focus on developing innovative therapies targeting FASN, a key pathway in various diseases, gives it a competitive edge in the market. Additionally, Sagimet's continued investment in research and development and partnerships with other biopharmaceutical companies further support its potential for growth and success in the pharmaceutical industry.

Bears say

Sagimet Biosciences is facing major competition in the acne treatment market, and their recent strategic pivot to prioritize acne over MASH is likely to face challenges in securing non-dilutive financing. While the positive Phase 3 trial results for denifanstat in acne are encouraging, the limited market penetration and slow projected growth may not justify the raised POS and peak sales estimates, making it difficult for the company to achieve its current high valuation. This, combined with the potential delays in the launch of denifanstat and concerns regarding TVB-3567 and the topical FASN program, contribute to a negative outlook on Sagimet's stock.

SGMT has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sagimet Biosciences Inc (SGMT) Forecast

Analysts have given SGMT a Buy based on their latest research and market trends.

According to 6 analysts, SGMT has a Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sagimet Biosciences Inc (SGMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.